PHILADELPHIA, November 29, 2021 – Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Sanford (Sandy) Zweifach has been appointed to the chairman position for the Board of Directors. Mr. Zweifach joins Carisma as a senior executive with 30 years in the...
PHILADELPHIA, November 12, 2021, 12:10 PM ET-- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today for the first time preliminary findings from the landmark Phase 1 multi-center clinical trial of CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric...
PHILADELPHIA, November 1, 2021 -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the acceptance of a late breaker abstract for oral presentation of its clinical study data and three pre-clinical study abstracts to be presented at the upcoming Society for...
Carisma Therapeutics Inc. announced today that that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) for the treatment of patients with solid tumors.
Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Richard Morris has been appointed Chief Financial Officer (CFO).
Carisma’s Chief Medical Officer, Debora Barton, MD, will be participating in a panel discussion on May 6 at 2:15 pm ET entitled “Cell & Gene Startups & Innovation in Cellicon Valley” alongside other industry leaders during Cellicon Valley ’21 Virtual Symposium.” We will also showcase a virtual exhibit about Carisma...